Lumos Pharma to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Lumos Pharma, a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, will participate in two upcoming investor conferences. The H.C. Wainwright 2022 Global Investment Conference will take place from May 23-26, with a live presentation scheduled for May 25 from 4:00 – 4:30 PM EDT. The Jefferies Healthcare Conference will follow from June 8-10, featuring a live fireside chat on June 8 at 3:30 – 3:55 PM EDT. Webcasts for both events can be accessed via the provided links. Lumos Pharma is developing LUM-201 for Pediatric Growth Hormone Deficiency, which has Orphan Drug Designation in the US and EU.

AUSTIN, Texas, May 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the following upcoming investors conferences:

Event:	H.C. Wainwright 2022 Global Investment Conference – May 23rd – 26th
Presentation:	Live presentation May 25th at 4:00 – 4:30 PM EDT
Webcast link:	Here
Event:	Jefferies Healthcare Conference – June 8th – 10th
Presentation:	Live fireside chat June 8th at 3:30 – 3:55 PM EDT
Webcast link:	Here

The webcasts for each presentation can also be found on the Company’s website under “Events & Presentations” in the Investors & Media section where a replay of each presentation will be also be available. Please contact your H.C. Wainwright or Jefferies salesperson, or Lumos Pharma Investor Relations, to schedule one-on-one meetings with the management team during the conferences or thereafter.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, a PK/PD trial, the OraGrowtH212 Trial, and a switch trial, the OraGrowtH213 Trial for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD patients otherwise endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com

Source: Lumos Pharma, Inc.

 

FAQ

What is Lumos Pharma's upcoming event schedule for May and June 2022?

Lumos Pharma will attend the H.C. Wainwright 2022 Global Investment Conference from May 23-26 and the Jefferies Healthcare Conference from June 8-10, 2022.

When will Lumos Pharma present at the H.C. Wainwright conference?

Lumos Pharma's live presentation at the H.C. Wainwright conference is set for May 25, 2022, from 4:00 – 4:30 PM EDT.

Where can I find Lumos Pharma's conference webcasts?

Webcasts for Lumos Pharma's conference presentations can be found through the provided links or on the company's website under the Investors & Media section.

What is the focus of Lumos Pharma's therapeutic candidate LUM-201?

LUM-201 targets Pediatric Growth Hormone Deficiency and aims to provide an oral alternative to injectable growth hormone treatments.

Has LUM-201 received any drug designations?

Yes, LUM-201 has received Orphan Drug Designation in both the US and EU.